The 5 0 untranslated region of the proto-oncogene c-myc contains an internal ribosome entry segment (IRES) and c-myc translation can therefore be initiated by internal ribosome entry as well as by cap-dependent mechanisms. It has been shown previously that in patients with multiple myeloma (MM) and in MM-derived cell lines there is a C to T mutation in the c-myc IRES that increases IRES activity and the corresponding synthesis of c-myc protein although it is not fully understood how this occurs. Our data show that two recently identified c-myc IRES transacting factors, Y-box binding protein 1 (YB-1) and polypyrimidine tract-binding protein 1 (PTB-1), bind more strongly (approximately 3.5-and 2-fold respectively) to the mutated version of the c-myc IRES and in vitro these proteins exert their effect synergistically to stimulate IRES activity of the mutant IRES 4.5-fold more than the wild-type version. Importantly, we show that there is a strong correlation between the expression of PTB-1, YB-1 and c-myc in MM-derived cell lines, suggesting that by reducing either PTB-1 or YB-1 protein levels it is possible to decrease c-myc expression and inhibit cell proliferation of MM-derived cell lines.
The protein encoded by the proto-oncogene c-myc is a transcription factor, and with its partner Max binds to E-box sequences with high affinity (Blackwood and Eisenman, 1991; reviewed in Meyer and Penn, 2008) . Recently, it has been shown that c-myc also has a role in DNA replication and control of S-phase progression (Vafa et al., 2002; reviewed in Herold et al., 2009) . Given these functions it is unsurprising that deregulated expression of c-myc is associated with many forms of neoplasia. Overexpression of c-myc can occur through a variety of mechanisms including insertional mutagenesis, gene amplification and chromosomal translocation (Meyer and Penn, 2008) . It has also been shown that c-myc protein levels can be upregulated in the absence of changes in RNA expression and half-life of the protein and therefore de-regulated expression of c-myc can also occur by changes in the rate of synthesis of the protein (Paulin et al., 1996) .
In eukaryotic cells, protein synthesis composed of three stages and the initiation of translation stage of this process has been shown to be the rate-limiting step. Initiation of translation can be mediated by either a capdependent mechanism, which is thought to require ribosome scanning (Sonenberg and Hinnebusch, 2009 ), or, alternatively, internal ribosome entry where the ribosome is recruited to a site that can be a considerable distance from the 5 0 end of the mRNA (Stoneley and Willis, 2004a) . For internal ribosome entry to occur a complex RNA structural element is required termed an internal ribosome entry segment (IRES). It has been shown that the 5 0 untranslated region of c-myc, which is encoded by exon 1, contains an IRES (Nanbru et al., 1997; Stoneley et al., 1998 ) that functions to maintain c-myc expression during a number of pathophysiological conditions including apoptosis , genotoxic stress (Subkhankulova et al., 2001 ) and viral infection (Johannes and Sarnow, 1998) . c-myc IRESmediated translation requires both canonical initiation factors (Spriggs et al., 2009 ) and specific IRES-transacting factors (ITAFs) and these have been shown to include Y-box binding protein 1 (YB-1), PSF, P54nrb, GRSF1, polypyrimidine tract-binding protein 1 (PTB-1), hnRNPK and hnRNPA1 (Evans et al., 2003; Cobbold et al., 2008; Jo et al., 2008) . It has been proposed that ITAFs stimulate IRES-mediated translation by acting as RNA chaperones and allowing the IRES to adopt the correct conformation so that the 40S ribosomal subunit can bind (Stoneley and Willis, 2004b) .
A mutated form of the c-myc IRES (a C to T transition at 2796 in the genomic sequence (Paulin et al., 1996 was identified in 42% of samples derived from patients with multiple myeloma (MM; an incurable disease which is characterized by bone marrow plasmacytosis, osteolytic lesions and secretion of a monoclonal immunoglobulin; Drach et al., 2000; Ho et al., 2002) and the data showed that the mutation increased IRES function and resulted in enhanced c-myc expression . Interestingly, the overexpression of c-myc mediated through the mutated IRES was shown to result from enhanced activity of the mutated version of the IRES Chappell et al., 2000) but other factors are clearly required as c-myc protein levels in cell lines derived from patients with MM which all harbour the mutation differ. The data suggest that this may be due to increased expression of c-myc ITAFs (Evans et al., 2003; Shi et al., 2008 ) and therefore we have investigated the interaction of the recently identified c-myc ITAFs PTB-1, PSF, YB-1 and p54nrb (Cobbold et al., 2008) with the mutated version of the c-myc IRES. We show that de-regulated expression of two these proteins is associated with aberrant c-myc protein expression in MM-derived cell lines.
A secondary structure model has been derived previously for the c-myc IRES (Figure 1a ; Le Quesne et al., 2001) and to determine with which domain the c-myc ITAFs PTB-1, YB-1, PSF, GRSF1 and p54nrb interacted, radiolabelled RNA was generated from full-length c-myc IRES RNA, domains 1 and 2, and electrophorectic mobility shift assays (EMSAs) were performed ( Figure 1b) . The data show that although all these ITAFs bind the full-length IRES as expected, GRSF, P54/nrb and PSF are unable to bind the separate fragments and it is possible that features in the ternary structure of the IRES-RNA are necessary for their interaction. In contrast, PTB-1 is able to bind both domain 1 and domain 2 and YB-1 interacts with domain 2 only (Figure 1b) .
The C-T mutation identified in the c-myc IRES in MM Chappell et al., 2000) is present in domain 2 of the IRES-RNA and results in an additional stem loop structure in this region (Figure 1c ; Chappell et al., 2000) . Because both PTB-1 and YB-1 bind to domain 2, EMSAs were then performed to determine the binding affinities of these proteins with both the wild-type and mutant forms of the IRES (Figures 1di and ei) . The data show that PTB-1 binds more strongly to the mutant version of the IRES and a lower concentration of PTB-1 is required to produce a slower migrating RNA species. In the case of YB-1 there is a greater binding to the mutated form of the c-myc IRES and even at the lowest concentration of protein used, a slower migrating RNA-protein complex was observed (Figure 1ei ). To investigate further the effect of the mutation in the c-myc IRES on the binding affinities of PTB-1 and YB-1, we performed filter binding assays to obtain dissociation constants for these two proteins (Figures 1dii and iii and eii and iii) . The data show that PTB-1 interacts 1.8-fold more strongly with the mutated form of the IRES whereas YB-1 binds 3.3 times more strongly (Figures 1dii and iii and eii and iii).
To determine whether these proteins stimulated the mutated version of the c-myc IRES to a greater extent than the wild-type IRES, we performed in vitro assays using RNA obtained from bicistronic vectors (Figure 2a) . We have shown previously that the addition of YB-1 to recticulocyte lysates stimulated c-myc IRES activity, but no effect was observed with PTB-1 (Cobbold et al., 2008) . It was suggested that this could be due to the relatively high levels of endogenous PTB-1 in the in vitro lysate system used (Cobbold et al., 2008) . Therefore to be able to assess the role of PTB-1 in IRESmediated translation initiation in vitro, this protein was immunoprecipitated from rabbit reticulocyte lysates using an anti-PTB-1 antibody ( Figure 2bi ). Interestingly, other c-myc ITAFs including YB-1, and PSF (but not p54nrb or GRSF1; data not shown), were coimmunoprecipitated from these lysates strongly suggesting that these proteins form part of a complex in vitro ( Figure 2bi ). RNA was generated from pRMF and pRMutF ( Figure 2ai ) and used to prime the depleted reticulocyte lysates that were supplemented with PTB-1, YB-1 or a combination of PTB-1 and YB-1 (Figures 2ci and ii). The data show that there was a synergistic effect with PTB-1 and YB-1 on the wild-type c-myc IRES and Quesne et al., 2001) shows that there are two structural motifs. These are termed domain 1 from 1 to 234 and domain 2 from 235 to 395. (b) RNA was generated from either the full-length c-myc IRES RNA or the domain 1 or domain 2. Electrophorectic mobility shift assays (EMSAs) were performed as described previously using approximately 23 000 c.p.m. of labelled transcript that was incubated with 0.4, 0.8, 1.6 and 2 mM of PTB-1, YB-1, PSF, GRSF or p54nrb (protein production has been described previously; Cobbold et al., 2008) at room temperature for 10 min. Loading buffer was added and samples were loaded directly onto 5 or 10% acrylamide TBE gels that were then electrophoresed at 150 V for 1 h. Gels were dried and exposed on a PhosphorImager (BioRad, Hemel Hemstead, Herts, UK). The data show that PTB-1 interacts with full-length RNA, and that derived from domain 1 and domain 2, whereas YB-1 interacts with full-length RNA and domain 2 RNA. (c) The mutation in the c-myc IRES found in patients with multiple myeloma is a C to T transition. This creates an additional stem loop in domain 2 (Chappell et al., 2000b) . (di) EMSAs were performed using radiolabelled RNA from either the wild-type (WT) or the mutated (MT) version of the c-myc IRES and increasing concentrations of PTB-1 (i). Dissociation constants were calculated for PTB-1 with the WT (ii) or the MT (iii) c-myc IRES using filter binding assays. Approximately 23 000 c.p.m. of labelled transcript was added to 10 ml of buffer mix containing 2 ml of 5X transcription buffer (200 mM Tris-HCl (pH 8.0), 40 mM MgCl 2 , 10 mM spermidine, 250 mM NaCl), 0.75 ml of 1 M DTT, 2 ml of tRNA (10 mg/ml), 1 ml of 10 mM rATP and 40 U of RNAsin. Recombinant PTB-1 between the range of 0.05 and 2 mg was then incubated with the mixture at room temperature for 10 min. Reactions were then filtered through a nitrocellulose membrane (0.45 mM pore size) pre-soaked in 1 Â binding/wash buffer (50 mM Tris-HCl (pH 8.0), 100 mM NaCl, 14.4 mM 2-mercaptoethanol). Membranes were washed with 0.5 ml of 1 Â binding/wash buffer. Membrane filters were air dried, and counted in a scintillation counter. A known volume of RNA was spotted onto a separate filter without washing to provide total input radioactivity. For the calculation of dissociation constants the fraction of bound RNA was determined from the scintillation reading. The data show that the mutated form of the IRES binds PTB-1 1.8-fold more strongly. (ei) EMSAs were carried out using radiolabelled RNA from WT or MT forms of the c-myc IRES and increasing concentrations of YB-1 (i).
(ii) and (iii) Dissociation constants were calculated using filter binding assays and the data show that YB-1 binds over three times more strongly to the mutated form of the IRES.
although each ITAF alone stimulated the c-myc IRES to a relatively small degree when added in combination there was an approximately sixfold stimulation of IRES activity (Figure 2ci ). The mutated version of the c-myc IRES was approximately 2-fold more active than the wild-type IRES before the addition of the ITAFs (in agreement with previous data; Chappell et al., 2000) , and upon the addition of PTB-1 there was a 15-fold stimulation of activity. Addition of YB-1 alone to the PTB-1-depleted extracts containing pRMutF resulted in a 3.5-fold stimulation of IRES activity however, when the proteins were added in combination there was again synergy and a 27-fold stimulation of IRES activity was observed (Figure 2cii ). These data show that the YB-1 and PTB-1 are essential for c-myc IRES function and that there is a 4.5-fold additional stimulation of c-myc mutant IRES activity when compared with the wild-type version in the presence of these proteins. These data are in agreement with the increased affinity of these proteins for the mutant version of the IRES (Figure 1) .
It would be expected that enhanced expression of PTB-1 and YB-1 would contribute to the elevated expression of c-myc found in some patients with MM and it has been shown previously Upregulated c-myc expression in multiple myeloma LC Cobbold et al that the mutation in the c-myc IRES alone is not sufficient to account for the large increase in c-myc protein levels in MM. Experiments were therefore performed to investigate the expression levels of YB-1 and PTB-1 in cell lines derived from patients with MM who harbour the mutated version of the c-myc IRES but have different levels of c-myc expression (Paulin et al., 1996) . Cell extracts were generated from either control B-cell lines (GM03201 and GM1953) or those derived from patients with MM that have low (GM1311), or high expression levels of c-myc (GM2132 and GM2132R5). Cell samples were harvested, lysed cells were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotted with the antibodies shown (Figure 3a ) and northern blot analysis was performed to assess the RNA levels of c-myc (Figure 3b ). In agreement with previous data, there is an increase in c-myc levels in cell lines derived from MM albeit with different extents from relatively low expression in GM1311 and high expression in GM2312R5 ( Figure 3a ) and no correlation with the expression of c-myc RNA (Figure 3b ). However, there is a good correlation with the degree of c-myc expression and that of PTB-1 and YB-1 (both the 50 and 37 kDa isoforms of The upstream cistron encodes Renilla luciferase, which will be translated in a capdependent manner, and the downstream cistron encodes firefly luciferase, which will be translated in a cap-independent manner. The wild-type (pRMF) or the mutated (pRMutF) versions of the c-myc IRESs were inserted between the two cistrons. (b) To deplete rabbit reticulocytes lysates of PTB-1, we incubated 500 ml of lysate with 100 ml of PTB-1 antibody overnight at 4 1C. Then 40 ml of protein A/G Sepharose was added and the lysate was incubated for 4 h at 4 1C. The A/G beads were harvested and PTB-1-depleted lysate was then used in translation reactions and in western blot analysis. Samples were taken at each stage and were then separated by SDSpolyacrylamide gel electrophoresis (PAGE) and immunoblotted to investigate whether PTB-1, YB-1 or PSF were removed from the extracts. (c) The PTB-1-depleted-extract was primed with 5 ng/ml of RNA and the total in vitro translation reaction was performed in a final volume of 12.5 ml and 200 ng of each protein was added where shown. Luciferase activities were assayed (using Promega Dual luciferase system, Promega, Southampton, UK), and the firefly and Renilla values were expressed relative to the plasmid pRMF where no protein had been added, which was assigned a value of 1. All experiments were performed in triplicate on at least three independent occasions. The data show that addition of PTB-1 and YB-1 individually to the depleted extracts increased the luciferase expression driven by the WT c-myc IRES 2-and 1.5-fold respectively; however when added in combination there was synergy and a 6.5-fold stimulation of IRES activity (i). Addition of PTB-1 or YB-1 individually to the depleted extracts that contained the mutated version of the c-myc IRES increased firefly luciferase expression 15-or 4-fold; however when added in combination there was more than 25-fold stimulation of IRES activity (ii).
this protein; Supplementary Information 1). The cell line GM2132R5 that has the highest level of c-myc shows the greatest increase in PTB-1 expression and YB-1 expression and in contrast, in the control Bcell line GM03201, YB-1, PTB-1 and c-myc expression is low (Figure 3a) . To determine whether overexpression of c-myc in MM resulted directly from the high levels of PTB-1 and YB-1, we used siRNA to reduce the expression of these proteins in GM2132 cells. The cells were lysed, separated by SDS-PAGE and immunoblotted with the antibodies shown (Figures 4ai and ii) . PTB-1 levels were reduced to o10% of the value in untreated cells and there was a large decrease in c-myc expression in the GM2132 MM-derived cell line and a smaller decrease in the GM03201 control cells (Figure 4ai ). There was no change in the c-myc mRNA levels, strongly suggesting that the decrease in the protein levels is due to altered translation (Figure 4bi ). It is known that in some cell types decrease of PTB-1 by siRNA results in increased expression of the nPTB paralog normally expressed in cells of neuronal origin (Boutz et al., 2007) . The data show that nPTB levels were increased in GM2132 cells and therefore to ensure that the decreased expression of c-myc did not result from the increase in nPTB levels, siRNA targeted to both PTB-1 and nPTB was used (Supplementary Information 2) . The data show that in all cases c-myc levels were reduced suggesting that nPTB cannot functionally replace PTB-1 in c-myc IRES activation (Supplementary Information 2) . The levels of YB-1 were reduced to approximately 50% of that observed in the control cells and it can be seen that in both the control cell line GM03201 and in the MMderived cell line GM2132 the level of c-myc protein is also reduced (Figure 4aii ). Again there was no change in the level of c-myc mRNA (Figure 4bii ) suggesting that the decrease in c-myc expression is due to altered translation of this protein.
We have shown that a reduction in YB-1 expression in NIH3T3 cells reduces cell proliferation (Cobbold et al., 2008) . To determine whether a similar effect is also observed in GM2132 (MM) and GM03201 (control) cells, we reduced the level of YB-1 by siRNA (as described in Supplementary Information 1) and measured the cell proliferation rates in cells treated with the siRNA against YB1-1 or the control siRNA using thymidine incorporation (Figures 4ci and ii) . The data show that, as expected, the proliferation rate of the MM-derived cell line was higher than the control cell line (Figure 4c ). A reduction in the level of YB-1 had decreased the translation rate of the MM-derived cell line although had a relatively small effect on the control cell line (Figures 4cii and iii) . These data agree with those shown previously (Chatterjee et al., 2008) .
To determine whether PTB-1 had a similar effect on proliferation rates of MM-derived cell lines, we reduced the levels of this protein using siRNA and carried out thymidine incorporation assays. The data show that there was a small effect on the control cell line proliferation rate (Figure 4di ). However there was a large effect on the proliferation rate of the MM-derived cell line and by 24 h there was sevenfold reduction in the proliferation rate (Figure 4dii) . A similar effect on cell proliferation was also observed in the MM-derived cell line GM1311 again with less effect observed with the control cell line GM1953 (Supplementary Information 3).
De-regulated c-myc expression in MM can occur by a number of different mechanisms and the data support a model in which this occurs as a late progression event that is associated with enhanced proliferation of the malignant cells (Kuehl and Bergsagel, 2002) . Our study data suggest that aberrant regulation of c-myc levels in a proportion of MM patients occurs at the level of translation . We now show that increased c-myc protein expression is mediated by enhanced binding to, and activation of, the mutated form of the c-myc IRES by the ITAFs PTB-1 and YB-1. The role of YB-1 in tumourigenesis is not entirely clear with some studies suggesting that this protein has tumour-promoting properties (Sutherland et al., 2005) while others showing a potent tumour-suppressive activity for this protein (Bader and Vogt, 2008) . However, a recent study has suggested that YB-1, in breast cancer cells that are hypoxic and derived of nutrients, represses cap-dependent translation and promotes IRES-mediated translation (Evdokimova et al., 2009) . Enforced YB-1-dependent IRES-mediated translation of specific mRNAs in breast tumours promoted epithelial-mesenchymal transition and metastatic spread (Evdokimova et al., 2009 ). In addition, it has been shown that in a subset of patients with MM, YB-1 is overexpressed, as well as in all cell lines tested (Chatterjee et al., 2008) in agreement with the data shown herein (Figure 3 ). Our study data and that of others have also shown that a decreased in YB-1 expression is associated with a decrease in cell Figure 3 There is a correlation between elevated levels of c-myc protein with polypyrimidine tract-binding protein 1 (PTB-1) and Y-box binding protein 1 (YB-1) expression. (a) Cell extracts were obtained from either control B-cell lines (GM03201, GM1953) or multiple myeloma (MM)-derived cells that had varying increases in c-myc protein expression but all contained the mutated form of the c-myc internal ribosome entry segment (IRES; GM1311, GM2132, GM2132R5; Paulin et al., 1998; GM2132 and GM2132R5 are also known as 8226 and 8226/R5; Dalton et al., 1986) . Samples were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotted with the antibodies shown. These data show that there is a good correlation between elevated c-myc expression and increased levels of PTB-1 and YB-1 isoforms (see Supplementary Information 1). (b) Northern analysis shows that there is no correlation between c-myc protein expression and c-myc mRNA levels.
proliferation (Chatterjee et al., 2008; Cobbold et al., 2008) Finally, YB-1 overexpression has been shown to contribute to resistance to apoptosis induced by doxyrubicin (Chatterjee et al., 2008) .
Similarly, PTB-1 overexpression has been implicated in tumourigenesis; it is overexpressed in certain cancers (He et al., 2007; Wang et al., 2008) and a reduction in PTB-1 expression in ovarian cancers reduces cell proliferation (He et al., 2007) . The data form our study show that a reduction in PTB-1 expression alone in cell lines derived from patients with MM had a dramatic effect on cell proliferation although, interestingly, there was little effect on the control B cells used. The reduced cell proliferation correlated with a decrease in c-myc expression due to the inhibition of IRES-mediated translation from mutated c-myc IRES. Taken together, 
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